Shares of Amgen Inc. (NASDAQ:AMGN) stepped higher following the release of its Q4 earnings report showing an EPS beat and a slight miss on sales.
The company reported, on a GAAP basis, a 2% decrease year-over-year in total operating expenses with a full year increase of 13% “primarily driven by the acquisition of Five Prime Therapeutics.” Amgen Chairman and CEO Robert Bradway highlighted, “strong volume growth for many of our key products during last year.”
